Pretreatment nomogram for predicting the outcome of three-dimensional conformal radiotherapy in prostate cancer
Pretreatment nomogram for predicting the outcome of three-dimensional conformal radiotherapy in prostate cancer
复制标题
DOI:
10.1200/jco.2000.18.19.3352
复制
发表时间:
2000-10-01
影响因子:
45.3
通讯作者:
Leibel, SA
中科院分区:
文献类型:
--
作者:
Kattan, MW;Zelefsky, MJ;Leibel, SA
Purpose: Several studies have defined risk groups for predicting the outcome after external-beam radiotherapy of localized prostate cancer. However, most models formed patient risk groups, and none of these models considers radiation dose as a predictor variable. The purpose of this study was to develop a nomogram to improve the accuracy of predicting outcome after three-dimensional conformal radiotherapy.Materials and Methods:This study was a retrospective, nonrandomized analysis of patients treated at the Memorial Sloan-Kettering Cancer Center between 1988 and 1998, Clinical parameters of the 1,042 patients included stage, biopsy Gleason score, pretreatment serum prostate-specific antigen (PSA) level, whether neoadjuvant androgen deprivation therapy was administered, and the radiation dose delivered. Biochemical (PSA) treatment failure was scored when three consecutive rises of serum PSA occurred. A nomogram, which predicts the probability of remaining free from biochemical recurrence for 5 years, was validated internally on this data set using ct bootstrapping method and externally using a cohort of patients treated at the Cleveland Clinic, Cleveland, OH.Results: When predicting outcomes for patients in the validation data set from the Cleveland Clinic, the nomogram had ct Somers' D rank correlation between predicted and observed failure times of 0.52. Predictions from this nomogram were more accurate (P